Satellos Bioscience Inc. MSLE
6.81 USD +0.06 (+0.95%)
Nov 12, 2026, 10:50 AM EST
6.61 Day range 7.07
5.30 52-week range 13.40
- YTD
- +15.88%
- 1 year
- +13.57%
News
benzinga.com Satellos Bioscience Q3 EPS $(0.53) Beats $(0.56) Estimate Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 35.9 percent decrease over losses of…
benzinga.com Satellos Bioscience Switches BASECAMP Phase 2 Primary Endpoint To MRI Fat Fraction Following FDA Feedback Fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadinProtocol amendment submitted to implement the new primary efficacy endpointTopline…- benzinga.com Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24 Craig-Hallum analyst Adam Vogel initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $24.
benzinga.com Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that…
benzinga.com Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment…- benzinga.com FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical needFSHD Canada Foundation to provide up to US$5 million in non-dilutive…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy and maintains $18 price target.
- benzinga.com Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 43.59 percent decrease over losses…
benzinga.com HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $18 HC Wainwright & Co. analyst Arthur He maintains Satellos Bioscience (NASDAQ:MSLE) with a Buy and raises the price target from $11 to $18.
benzinga.com Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence Satellos reports six-month interim data showing SAT-3247 improved muscle composition, maintained strength, and remained well-tolerated in DMD.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Innovative Eyewear (NASDAQ:LUCY)…
benzinga.com Satellos Bioscience Announces Six-Month Interim Data From TRAILHEAD Evaluating SAT-3247 In Adults With Duchenne Muscular Dystrophy; All Four Participants Showed Decline In Fat Fraction As Measured By MRI Fat fraction mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesting improved muscle compositionAll four participants showed an increase in TE99C, a measure of…- benzinga.com Satellos Gets FDA Fast Track Status For Duchenne Drug Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced
- benzinga.com HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $11 Price Target HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy and maintains $11 price target.
benzinga.com Earnings Scheduled For May 15, 2026 - benzinga.com Satellos Bioscience Q1 EPS $(0.53) Down From $(0.44) YoY Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.53) per share. This is a 20.45 percent decrease over losses of $(0.44) per share from the same period last year.
- benzinga.com Guggenheim Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $23 Guggenheim analyst Debjit Chattopadhyay initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $23.
benzinga.com HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $11 HC Wainwright & Co. analyst Arthur He maintains Satellos Bioscience (NASDAQ:MSLE) with a Buy and raises the price target from $1.2 to $11.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst ratings page. Analysts' thoughts on LGND stock.- benzinga.com Cantor Fitzgerald Initiates Coverage On Satellos Bioscience with Overweight Rating Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Overweight rating.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session